Table 3 Univariate logistic regression for the predicting of a pCR irrespective of study treatment
pCR | Odds ratio | 95% CI | ||
|---|---|---|---|---|
n | % | |||
Menopausal status: | ||||
Premenopausal | 12 | 11.3 | 2.17 | 0.73 to 6.41 |
Peri-/postmenopausal | 5 | 5.6 | ||
Clinical tumour size: | ||||
≤ 4 cm | 12 | 10.5 | 1.81 | 0.61 to 5.36 |
> 4 cm | 5 | 6.1 | ||
Clinical nodal status: | ||||
Negative | 14 | 14.3 | 5.28 | 1.47 to 19.00 |
Positive | 3 | 3.1 | ||
Grading: | ||||
Grade I + II | 2 | 2.2 | 0.13 | 0.03 to 0.61 |
Grade III | 15 | 14.4 | ||
Clinical response after: 2 cycles ddAT | ||||
cCR/cPR | 12 | 12.6 | 3.07 | 0.95 to 9.91 |
cNC/cPD | 4 | 4.5 | ||
ER: | ||||
0 to 9% | 15 | 17.4 | 11.41 | 2.53 to 51.41 |
10 to 100% | 2 | 1.8 | ||
PgR: | ||||
0 to 9% | 16 | 13.5 | 11.81 | 1.53 to 90.97 |
10 to 100% | 1 | 1.3 | ||
Ki-67: | ||||
0 to 15% | 3 | 4.0 | 0.32 | 0.09 to 1.15 |
16 to 100% | 14 | 11.6 | ||
HER2: | ||||
0 to 2+ | 15 | 10.1 | 2.48 | 0.55 to 11.28 |
3+ | 2 | 4.3 | ||
p53: | ||||
1 to 50% | 5 | 5.5 | 0.45 | 0.15 to 1.33 |
0 + 51 to 100% | 12 | 11.4 | ||
bcl-2: | ||||
0 to 1+ | 16 | 12.9 | 10.52 | 1.36 to 81.09 |
2 to 3+ | 1 | 1.4 | ||